Document is current

Article History

Received: 17 August 2023

Accepted: 16 February 2024

First Online: 27 February 2024

Declarations

:

: The study protocol has been approved by the Institutional Review Board at the University of Kansas Medical Center. Informed consent is obtained from all participants prior to participating in this study. Participants also have the option to consent to storage of collected biological specimens for use in future ancillary studies. All protocol modifications will be approved by the investigators and submitted to the Institutional Review Board at the University of Kansas Medical Center for approval. All active participants will be re-consented with updated consent forms reflecting protocol changes.

: Not applicable.

: M. K. T. receives research support from the National Institutes of Health (NIH) and the Alzheimer’s Association. In the past 2 years, J. M. B. has received research support from the NIH; research support to conduct clinical trials (paid to institution) from Eli Lilly, Amylyx Pharmaceuticals, Biogen, AbbVie, Astra-Zeneca, and Roche; and has served as a consultant for Renew Research, Amylyx Pharmaceuticals, Eisai, and Eli Lilly. I. Y. C. receives research support from the NIH and the US Highbush Blueberry Council. T. J. H. receives support from the National Strength and Conditioning Association. P. L. receives research support from the NIH. A. N. S. declares no competing interests. D. K. S. receives research support from the NIH, the Egg Nutrition Center, and the US Highbush Blueberry Council. R. H. S. receives research support from the NIH. H. M. W. receives research support from the NIH and the Alzheimer’s Association.